尿激酶介入治疗在急性脑梗死患者中的应用效果及对神经损伤的影响

Effect of Urokinase Interventional Therapy in Patients with Acute Cerebral Infarction and Its Effect on Nerve Injury

目的:探讨尿激酶介入治疗方法对急性脑梗死患者的临床疗效和神经损伤的实际影响。方法:选取本院2017年6月-2020年5月急诊收治的脑梗死患者228例为研究对象,根据临床救治方法差异将其分成研究组(给予尿激酶介入治疗)和对照组(给予常规治疗),每组114例。对两组患者的临床综合疗效、不良反应以及治疗前后的神经功能情况、神经保护因子等指标进行观察和比较。结果:研究组患者治疗第7、14天的临床总有效率分别为59.65%和81.58%,均高于对照组患者的38.60%和61.40%,差异均有统计学意义(P<0.05)。治疗第7、14天,研究组患者的NIHSS评分和MMSE评分均优于对照组,差异均有统计学意义(P<0.05)。治疗第7、14天,研究组患者的UCH-L1、CFAP、BDNF和IGF-1均优于对照组,差异均有统计学意义(P<0.05)。结论:采用尿激酶介入治疗急性脑梗死患者,能够有效提升临床综合疗效,显著促进患者神经功能的恢复,改善患者神经保护因子,是临床治疗急性脑梗死的理想方案之一。

Objective:To explore the clinical efficacy and practical effect of Urokinase interventional therapy on nerve injury in patients with acute cerebral infarction.Method:From June 2017 to May 2020,228 patients with cerebral infarction treated in the emergency department of the hospital were selected as the research objects,according to the difference of clinical treatment methods,they were divided into the study group (given Urokinase intervention treatment) and the control group (given routine treatment),with 114 patients in each group.The clinical comprehensive efficacy,adverse reactions,neurological function evaluation results and neuroprotective factors before and after treatment were observed and compared between the two groups.Result:The total clinical effective rate of study group on the 7th and 14th day of treatment was 59.65% and 81.58%,respectively,which were higher than 38.60% and 61.40% of control group,the differences were statistically significant (P<0.05).On the 7th and 14th day of treatment,NIHSS score and MMSE score of patients in the study group were better than those in the control group,the differences were statistically significant (P<0.05).On the 7th and 14th day of treatment,UCH-L1,CFAP,BDNF and IGF-1 of patients in the study group were better than those in the control group,the differences were statistically significant (P<0.05).Conclusion:Interventional treatment of patients with acute cerebral infarction with Urokinase can effectively improve clinical comprehensive efficacy,significantly promote the recovery of patients’ neurological function,improve patients’ neuroprotective factors,is one of the ideal clinical treatment of acute cerebral infarction.